Paragon Advisors LLC Decreases Holdings in Veeva Systems Inc. $VEEV

Paragon Advisors LLC reduced its position in Veeva Systems Inc. (NYSE:VEEV) by 24.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,607 shares of the technology company’s stock after selling 2,838 shares during the period. Paragon Advisors LLC’s holdings in Veeva Systems were worth $2,564,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Veeva Systems by 1.4% in the second quarter. Vanguard Group Inc. now owns 14,971,425 shares of the technology company’s stock valued at $4,311,471,000 after buying an additional 210,859 shares in the last quarter. Alliancebernstein L.P. raised its position in Veeva Systems by 3.7% during the second quarter. Alliancebernstein L.P. now owns 5,705,648 shares of the technology company’s stock worth $1,643,113,000 after acquiring an additional 205,997 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Veeva Systems by 2.6% in the second quarter. JPMorgan Chase & Co. now owns 3,316,274 shares of the technology company’s stock valued at $955,030,000 after purchasing an additional 85,516 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Veeva Systems by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock worth $888,108,000 after purchasing an additional 114,003 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Veeva Systems by 111.7% during the 2nd quarter. AQR Capital Management LLC now owns 1,838,046 shares of the technology company’s stock worth $526,508,000 after purchasing an additional 969,905 shares in the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Veeva Systems Stock Down 0.1%

NYSE:VEEV opened at $217.66 on Thursday. The company has a market cap of $35.78 billion, a P/E ratio of 42.35, a P/E/G ratio of 1.61 and a beta of 1.07. The firm’s 50 day moving average is $229.28 and its two-hundred day moving average is $265.65. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The business had revenue of $0.81 million for the quarter, compared to analyst estimates of $792.37 million. During the same period last year, the company posted $1.75 EPS. The business’s quarterly revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Research analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems announced that its Board of Directors has initiated a stock repurchase plan on Monday, January 5th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the technology company to repurchase up to 5.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, insider Thomas D. Schwenger sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total transaction of $231,430.00. Following the completion of the sale, the insider owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays lowered their target price on Veeva Systems from $325.00 to $305.00 and set an “overweight” rating on the stock in a report on Friday, November 21st. BMO Capital Markets initiated coverage on Veeva Systems in a research report on Thursday, November 13th. They set a “market perform” rating and a $300.00 price objective for the company. Wells Fargo & Company reduced their target price on shares of Veeva Systems from $341.00 to $333.00 and set an “overweight” rating on the stock in a report on Tuesday, November 25th. Wall Street Zen downgraded shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Finally, William Blair reissued an “outperform” rating on shares of Veeva Systems in a research report on Friday, October 17th. Eighteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $308.04.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.